Therapeutic Potential of Nanomedicine in Management of Alzheimer’s Disease and Glioma

References

• Prasad K. AGE–RAGE stress: A changing landscape in pathology and treatment of Alzheimer’s disease. Mol Cell Biochem. 2019;459(1):95–112. doi:10.1007/s11010-019-03553-4
   PubMed Web of Science ®Google Scholar
• Ladomersky E, Scholtens DM, Kocherginsky M, et al. The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma. Front Pharmacol. 2019;10:200. doi:10.3389/fphar.2019.00200
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Ziech D, Franco R, Pappa A, et al. Reactive Oxygen Species (ROS)––Induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res. 2011;711(1–2):167–173. doi:10.1016/j.mrfmmm.2011.02.015
   PubMed Web of Science ®Google Scholar
• Nikitovic D, Tzardi M, Berdiaki A, et al. Cancer microenvironment and inflammation: role of hyaluronan. Front Immunol. 2015;6:169. doi:10.3389/fimmu.2015.00169
   PubMed Web of Science ®Google Scholar
• Franceschi AM. Hybrid PET/MR Neuroimaging: A Comprehensive Approach. Springer Nature; 2022.
   Google Scholar
• Cheignon CM, Tomas M, Bonnefont-Rousselot D, et al. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 2018;14(p):450–464. doi:10.1016/j.redox.2017.10.014
   PubMedGoogle Scholar
• Matej R, Tesar A, Rusina R. Alzheimer’s disease and other neurodegenerative dementias in comorbidity: a clinical and neuropathological overview. Clin Biochem. 2019;73:26–31. doi:10.1016/j.clinbiochem.2019.08.005
   PubMed Web of Science ®Google Scholar
• Balschun D, Rowan MJ. Hippocampal synaptic plasticity in neurodegenerative diseases: Amyloid-Β, tau and beyond that. Neuroforum. 2018;24(3):203–212. doi:10.1515/nf-2017-0063
   Google Scholar
• Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Neurosci. 2020;23(10):1183–1193. doi:10.1038/s41593-020-0687-6
   PubMed Web of Science ®Google Scholar
• Balducci C, Beeg M, Stravalaci M, et al. Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci. 2010;107(5):2295–2300. doi:10.1073/pnas.0911829107
   PubMed Web of Science ®Google Scholar
• Viola KL, Klein WL. Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129(2):183–206. doi:10.1007/s00401-015-1386-3
   PubMed Web of Science ®Google Scholar
• Saykin AJ, Shen L, Yao X, et al. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimers Dement. 2015;11(7):792–814. doi:10.1016/j.jalz.2015.05.009
   PubMed Web of Science ®Google Scholar
• Azhdarzadeh M, Noroozian M, Aghaverdi H, et al. Serum Multivalent Cationic Pattern: Speculation on the Efficient Approach for Detection of Alzheimer’s Disease. Sci Rep. 2013;3(1):1–6. doi:10.1038/srep02782
   Google Scholar
• Nie J. Exposure to aluminum in daily life and Alzheimer’s disease, in Neurotoxicity of Aluminum. Springer; 2018:99–111.
   Google Scholar
• Ladomersky E, Zhai L, Lauing KL, et al. Advanced age increases immunosuppression in the brain and decreases immunotherapeutic efficacy in subjects with glioblastoma. Clin Cancer Res. 2020;26(19):5232–5245. doi:10.1158/1078-0432.CCR-19-3874
   PubMed Web of Science ®Google Scholar
• Gaist D, Andersen L, Hallas J, et al. Use of statins and risk of glioma: a nationwide case–control study in Denmark. Br J Cancer. 2013;108(3):715–720. doi:10.1038/bjc.2012.536
   PubMed Web of Science ®Google Scholar
• Silvera SAN, Miller AB, Rohan TE. Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Int J Cancer. 2006;118(5):1321–1324. doi:10.1002/ijc.21467
   PubMed Web of Science ®Google Scholar
• Cha GD, Kang T, Baik S, et al. Advances in drug delivery technology for the treatment of glioblastoma multiforme. J Control Release. 2020;328:350–367. doi:10.1016/j.jconrel.2020.09.002
   PubMed Web of Science ®Google Scholar
• Mecca C, Giambanco I, Bruscoli S, et al. PP242 counteracts glioblastoma cell proliferation, migration, invasiveness and stemness properties by inhibiting mTORC2/AKT. Front Cell Neurosci. 2018;12:99. doi:10.3389/fncel.2018.00099
   PubMed Web of Science ®Google Scholar
• Scoccianti S, Francolini G, Carta GA, et al. Re-irradiation as salvage treatment in recurrent glioblastoma: a comprehensive literature review to provide practical answers to frequently asked questions. Crit Rev Oncol Hematol. 2018;126(p):80–91. doi:10.1016/j.critrevonc.2018.03.024
   PubMedGoogle Scholar
• Zhang P, Xia Q, Liu L, et al. Current opinion on molecular characterization for GBM classification in guiding clinical diagnosis, prognosis, and therapy. Front Mol Biosci. 2020;2020:241.
   Google Scholar
• Buszek SM, Al Feghali KA, Elhalawani H, et al. Optimal timing of radiotherapy following gross total or subtotal resection of glioblastoma: a real-world assessment using the National Cancer Database. Sci Rep. 2020;10(1):1–9. doi:10.1038/s41598-020-61701-z
   PubMed Web of Science ®Google Scholar
• He H, Li J, Jiang P, et al. The basis and advances in clinical application of boron neutron capture therapy. Radiat Oncol. 2021;16(1):1–8. doi:10.1186/s13014-021-01939-7
   PubMed Web of Science ®Google Scholar
• Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13. doi:10.1016/j.jocn.2018.05.002
   PubMed Web of Science ®Google Scholar
• Arora L, Kumar A, Arfuso F, et al. The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies. Cancers. 2018;10(9):327. doi:10.3390/cancers10090327
   PubMed Web of Science ®Google Scholar
• Zhang J, Sikka S, Siveen KS, et al. Cardamonin represses proliferation, invasion, and causes apoptosis through the modulation of signal transducer and activator of transcription 3 pathway in prostate cancer. Apoptosis. 2017;22(1):158–168. doi:10.1007/s10495-016-1313-7
   PubMed Web of Science ®Google Scholar
• Grabowski MM, Sankey EW, Ryan KJ, et al. Immune suppression in gliomas. J Neurooncol. 2021;151(1):3–12. doi:10.1007/s11060-020-03483-y
   PubMed Web of Science ®Google Scholar
• West AJ, Tsui V, Stylli SS, et al. The role of interleukin‑6‑STAT3 signalling in glioblastoma. Oncol Lett. 2018;16(4):4095–4104. doi:10.3892/ol.2018.9227
   PubMed Web of Science ®Google Scholar
• Wu J, Feng X, Zhang B, et al. Blocking the bFGF/STAT3 interaction through specific signaling pathways induces apoptosis in glioblastoma cells. J Neurooncol. 2014;120(1):33–41. doi:10.1007/s11060-014-1529-8
   PubMed Web of Science ®Google Scholar
• Birner P, Toumangelova-Uzeir K, Natchev S, et al. STAT3 tyrosine phosphorylation influences survival in glioblastoma. J Neurooncol. 2010;100(3):339–343. doi:10.1007/s11060-010-0195-8
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhao BS, Zhou A, et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer cell. 2017;31(4):591–606. e6. doi:10.1016/j.ccell.2017.02.013
   PubMed Web of Science ®Google Scholar
• Dai Z, Wang L, Wang X, et al. Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3. Oncol Rep. 2018;40(2):867–876. doi:10.3892/or.2018.6512
   PubMed Web of Science ®Google Scholar
• Mashimo T, Pichumani K, Vemireddy V, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159(7):1603–1614. doi:10.1016/j.cell.2014.11.025
   PubMed Web of Science ®Google Scholar
• Han D, Yu T, Dong N, et al. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019;38(1):1–12. doi:10.1186/s13046-019-1289-6
   PubMedGoogle Scholar
• Ibáñez K, Boullosa C, Tabarés-Seisdedos R, et al. Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. PLoS Genet. 2014;10(2):e1004173. doi:10.1371/journal.pgen.1004173
   PubMed Web of Science ®Google Scholar
• Zhang L, Silva TC, Young JI, et al. Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer’s disease. Nat Commun. 2020;11(1):1–13. doi:10.1038/s41467-020-19791-w
   PubMed Web of Science ®Google Scholar
• Wan Y-W, Al-Ouran R, Mangleburg CG, et al. Meta-analysis of the Alzheimer’s disease human brain transcriptome and functional dissection in mouse models. Cell Rep. 2020;32(2):107908. doi:10.1016/j.celrep.2020.107908
   PubMed Web of Science ®Google Scholar
• Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab. 2006;7(2):183–203. doi:10.2174/138920006775541525
   PubMed Web of Science ®Google Scholar
• Campisi M, Shin Y, Osaki T, et al. 3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes. Biomaterials. 2018;180:117–129. doi:10.1016/j.biomaterials.2018.07.014
   PubMed Web of Science ®Google Scholar
• Jamieson JJ, Linville RM, Ding YY, et al. Role of iPSC-derived pericytes on barrier function of iPSC-derived brain microvascular endothelial cells in 2D and 3D. Fluids Barriers CNS. 2019;16(1):1–16. doi:10.1186/s12987-019-0136-7
   PubMedGoogle Scholar
• Gosselet F, Loiola RA, Roig A, et al. Central nervous system delivery of molecules across the blood-brain barrier. Neurochem Int. 2021;144:104952. doi:10.1016/j.neuint.2020.104952
   PubMed Web of Science ®Google Scholar
• Loryan I, Reichel A, Feng B, et al. Unbound Brain-to-Plasma Partition Coefficient, Kp, uu, brain—a Game Changing Parameter for CNS Drug Discovery and Development. Pharm Res. 2022;39(7):1321–1341. doi:10.1007/s11095-022-03246-6
   PubMed Web of Science ®Google Scholar
• Pan Y, Nicolazzo JA. Impact of aging, Alzheimer’s disease and Parkinson’s disease on the blood-brain barrier transport of therapeutics. Adv Drug Deliv Rev. 2018;135:62–74. doi:10.1016/j.addr.2018.04.009
   PubMed Web of Science ®Google Scholar
• Afzal M, Alharbi KS, Alruwaili NK, et al. Nanomedicine in treatment of breast cancer–A challenge to conventional therapy. In: Seminars in cancer biology. Elsevier; 2021.
   Google Scholar
• Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell cycle. 2007;6(9):1006–1010. doi:10.4161/cc.6.9.4211
   PubMed Web of Science ®Google Scholar
• Kamat CD, Green DE, Warnke L, et al. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007;249(2):209–219. doi:10.1016/j.canlet.2006.08.017
   PubMed Web of Science ®Google Scholar
• Fu X, Wu S, Li B, et al. Functions of p53 in pluripotent stem cells. Protein Cell. 2020;11(1):71–78. doi:10.1007/s13238-019-00665-x
   PubMed Web of Science ®Google Scholar
• Vancsik T, Forika G, Balogh A, et al. Modulated electro‐hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro. Cancer Med. 2019;8(9):4292–4303. doi:10.1002/cam4.2330
   PubMed Web of Science ®Google Scholar
• Tsabar M, Mock CS, Venkatachalam V, et al. A switch in p53 dynamics marks cells that escape from DSB-induced cell cycle arrest. Cell Rep. 2020;32(5):107995. doi:10.1016/j.celrep.2020.107995
   PubMed Web of Science ®Google Scholar
• Das S, Shukla N, Singh SS, et al. Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis. 2021;26(9–10):512–533. doi:10.1007/s10495-021-01687-9
   PubMed Web of Science ®Google Scholar
• Liu L, Yan J, Cao Y, et al. Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways. Oncol Lett. 2021;21(1):1. doi:10.3892/ol.2020.12262
   PubMed Web of Science ®Google Scholar
• Deng Z, Wang H, Liu J, et al. Comprehensive understanding of anchorage-independent survival and its implication in cancer metastasis. Cell Death Dis. 2021;12(7):1–12. doi:10.1038/s41419-021-03890-7
   PubMed Web of Science ®Google Scholar
• Tauffenberger A, Magistretti PJ. Reactive oxygen species: beyond their reactive behavior. Neurochem Res. 2021;46(1):77–87. doi:10.1007/s11064-020-03208-7
   PubMed Web of Science ®Google Scholar
• Lisek K, Campaner E, Ciani Y, et al. Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. Oncotarget. 2018;9(29):20508. doi:10.18632/oncotarget.24974
   PubMedGoogle Scholar
• Jembrek MJ, Slade N, Hof PR, et al. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease. Prog Neurobiol. 2018;168:104–127. doi:10.1016/j.pneurobio.2018.05.001
   PubMed Web of Science ®Google Scholar
• Erekat NS. Apoptosis and its therapeutic implications in neurodegenerative diseases. Clin Anat. 2022;35(1):65–78. doi:10.1002/ca.23792
   PubMed Web of Science ®Google Scholar
• Tajbakhsh A, Read M, Barreto GE, et al. Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer’s disease: Pathological mechanisms and therapeutic outlooks. Eur J Pharmacol. 2021;895:173873. doi:10.1016/j.ejphar.2021.173873
   PubMed Web of Science ®Google Scholar
• Singh BK, Vatsa N, Kumar V, et al. Ube3a deficiency inhibits amyloid plaque formation in APPswe/PS1δE9 mouse model of Alzheimer’s disease. Hum Mol Genet. 2017;26(20):4042–4054. doi:10.1093/hmg/ddx295
   PubMed Web of Science ®Google Scholar
• Yang DS, Saeedi A, Davtyan A, et al. Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils. Proc Natl Acad Sci. 2021;118(10):1.
   Web of Science ®Google Scholar
• Zajkowicz A, Gdowicz-Kłosok A, Krześniak M, et al. The Alzheimer’s disease-associated TREM2 gene is regulated by p53 tumor suppressor protein. Neurosci Lett. 2018;681:62–67. doi:10.1016/j.neulet.2018.05.037
   PubMed Web of Science ®Google Scholar
• Zarrouk A, Hammouda S, Ghzaiel I, et al. Association between oxidative stress and altered cholesterol metabolism in Alzheimer’s disease patients. Curr Alzheimer Res. 2021;17(9):823–834. doi:10.2174/1567205017666201203123046
   Web of Science ®Google Scholar
• Amor-Gutiérrez O, Costa-Rama E, Arce-Varas N, et al. Competitive electrochemical immunosensor for the detection of unfolded p53 protein in blood as biomarker for Alzheimer’s disease. Anal Chim Acta. 2020;1093:28–34. doi:10.1016/j.aca.2019.09.042
   PubMed Web of Science ®Google Scholar
• Li X, Gong X, Chen J, et al. miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2. Biochem Biophys Res Commun. 2015;460(3):670–677. doi:10.1016/j.bbrc.2015.03.088
   PubMed Web of Science ®Google Scholar
• Sittithumcharee G, Suppramote O, Vaeteewoottacharn K, et al. Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity. Hepatology. 2019;70(5):1614–1630. doi:10.1002/hep.30704
   PubMed Web of Science ®Google Scholar
• Chu C, Geng Y, Zhou Y, et al. Cyclin E in normal physiology and disease states. Trends Cell Biol. 2021;31(9):732–746. doi:10.1016/j.tcb.2021.05.001
   PubMed Web of Science ®Google Scholar
• Bai J, Li Y, Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. 2017;14(4):348. doi:10.20892/j.issn.2095-3941.2017.0033
   PubMed Web of Science ®Google Scholar
• Tan X, Luo Q, Zhou S, et al. Erchen plus huiyanzhuyu decoction inhibits the growth of laryngeal carcinoma in a mouse model of phlegm-coagulation-blood-stasis syndrome via the STAT3/Cyclin D1 pathway. Evid Based Complement Alternat Med. 2020;2020:1–14. doi:10.1155/2020/2803496
   Web of Science ®Google Scholar
• Bouclier C, Simon M, Laconde G, et al. Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. Theranostics. 2020;10(5):2008. doi:10.7150/thno.40971
   PubMed Web of Science ®Google Scholar
• Laphanuwat P, Likasitwatanakul P, Sittithumcharee G, et al. Cyclin D1 depletion interferes with oxidative balance and promotes cancer cell senescence. J Cell Sci. 2018;131(12):jcs214726. doi:10.1242/jcs.214726
   PubMed Web of Science ®Google Scholar
• Absalon S, Kochanek DM, Raghavan V, et al. MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. 2013;33(37):14645–14659. doi:10.1523/JNEUROSCI.1327-13.2013
   PubMed Web of Science ®Google Scholar
• Ciapa B, Granon S. Expression of cyclin-D1 in astrocytes varies during aging. Front Aging Neurosci. 2018;10:104. doi:10.3389/fnagi.2018.00104
   PubMed Web of Science ®Google Scholar
• Heo SY, Jeong M-S, Lee HS, et al. Dieckol induces cell cycle arrest by down-regulating CDK 2/cyclin E in response to p21/p53 activation in human tracheal fibroblasts. Cell Biochem Funct. 2022;40(1):71–78. doi:10.1002/cbf.3675
   PubMed Web of Science ®Google Scholar
• Chen X, Low K-H, Alexander A, et al. Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition. Clin Cancer Res. 2018;24(24):6594–6610. doi:10.1158/1078-0432.CCR-18-1446
   PubMed Web of Science ®Google Scholar
• Min A, Kim JE, Kim Y-J, et al. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. Cancer Lett. 2018;430:123–132. doi:10.1016/j.canlet.2018.04.037
   PubMed Web of Science ®Google Scholar
• Albero R, Enjuanes A, Demajo S, et al. Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. J Clin Invest. 2018;128(9):4132–4147. doi:10.1172/JCI96520
   PubMed Web of Science ®Google Scholar
• Tao JL, Luo M, Sun H, et al. Overexpression of tripartite motif containing 26 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling. Kaohsiung J Med Sci. 2020;36(6):417–422. doi:10.1002/kjm2.12194
   PubMed Web of Science ®Google Scholar
• Jian Z, Zhang L, Jin L, et al. Rab5 regulates the proliferation, migration and invasion of glioma cells via cyclin E. Oncol Lett. 2020;20(2):1055–1062. doi:10.3892/ol.2020.11660
   PubMed Web of Science ®Google Scholar
• Lee C, Fernandez KJ, Alexandrou S, et al. Cyclin E2 promotes whole genome doubling in breast cancer. Cancers. 2020;12(8):2268. doi:10.3390/cancers12082268
   PubMed Web of Science ®Google Scholar
• Dong L, Yu L, Bai C, et al. USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis. Oncogene. 2018;37(20):2702–2713. doi:10.1038/s41388-018-0137-z
   PubMed Web of Science ®Google Scholar
• Li S, Zhang H, Wei X. Roles and Mechanisms of Deubiquitinases (DUBs) in Breast Cancer Progression and Targeted Drug Discovery. Life. 2021;11(9):965. doi:10.3390/life11090965
   PubMedGoogle Scholar
• Glasgow SD, Ruthazer ES, Kennedy TE. Guiding synaptic plasticity: Novel roles for netrin‐1 in synaptic plasticity and memory formation in the adult brain. J Physiol. 2021;599(2):493–505. doi:10.1113/JP278704
   PubMed Web of Science ®Google Scholar
• Nangia V, O’Connell J, Chopra K, et al. Genetic reduction of tyramine β hydroxylase suppresses Tau toxicity in a Drosophila model of tauopathy. Neurosci Lett. 2021;755:135937. doi:10.1016/j.neulet.2021.135937
   PubMed Web of Science ®Google Scholar
• John A, Reddy PH. Synaptic basis of Alzheimer’s disease: Focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res Rev. 2021;65:101208. doi:10.1016/j.arr.2020.101208
   PubMed Web of Science ®Google Scholar
• Li Y, Guo H, Wang Z, et al. Cyclin F and KIF20A, FOXM1 target genes, increase proliferation and invasion of ovarian cancer cells. Exp Cell Res. 2020;395(2):112212. doi:10.1016/j.yexcr.2020.112212
   PubMed Web of Science ®Google Scholar
• Walter D, Hoffmann S, Komseli E-S, et al. SCFCyclin F-dependent degradation of CDC6 suppresses DNA re-replication. Nat Commun. 2016;7(1):1–10. doi:10.1038/ncomms10530
   Google Scholar
• Galper J, Rayner SL, Hogan AL, et al. Cyclin F: a component of an E3 ubiquitin ligase complex with roles in neurodegeneration and cancer. Int J Biochem Cell Biol. 2017;89:216–220. doi:10.1016/j.biocel.2017.06.011
   PubMed Web of Science ®Google Scholar
• Deshmukh RS, Sharma S, Das S. Cyclin F-dependent degradation of RBPJ inhibits IDH1R132H-mediated tumorigenesis. Cancer Res. 2018;78(22):6386–6398. doi:10.1158/0008-5472.CAN-18-1772
   PubMed Web of Science ®Google Scholar
• Han CH, Batchelor TT. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas. Chin Clin Oncol. 2017;6(3):33. doi:10.21037/cco.2017.06.11
   PubMedGoogle Scholar
• Mackenzie IR, Nicholson AM, Sarkar M, et al. TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron. 2017;95(4):808–816. e9. doi:10.1016/j.neuron.2017.07.025
   PubMed Web of Science ®Google Scholar
• Sørensen MF, Heimisdóttir SB, Sørensen MD, et al. High expression of cystine–glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma. J Neurooncol. 2018;138(1):49–53. doi:10.1007/s11060-018-2785-9
   PubMed Web of Science ®Google Scholar
• Robert SM, Sontheimer H. Glutamate transporters in the biology of malignant gliomas. Cell Mol Life Sci. 2014;71(10):1839–1854. doi:10.1007/s00018-013-1521-z
   PubMed Web of Science ®Google Scholar
• Savaskan N E, Fan Z, Broggini T, et al. Neurodegeneration in the brain tumor microenvironment: glutamate in the limelight. Curr Neuropharmacol. 2015;13(2):258–265. doi:10.2174/1570159X13666150122224158
   PubMed Web of Science ®Google Scholar
• Belov Kirdajova D, Kriska J, Tureckova J, Anderova M. Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci. 2020;14:51. doi:10.3389/fncel.2020.00051
   PubMed Web of Science ®Google Scholar
• Lange F, Hörnschemeyer J, Kirschstein T. Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. Cells. 2021;10(5):1226. doi:10.3390/cells10051226
   PubMed Web of Science ®Google Scholar
• Tawfik A, Mohamed R, Kira D, et al. N-Methyl-D-aspartate receptor activation, novel mechanism of homocysteine-induced blood–retinal barrier dysfunction. J Mol Med. 2021;99(1):119–130. doi:10.1007/s00109-020-02000-y
   PubMed Web of Science ®Google Scholar
• Shafiei-Irannejad V, Abbaszadeh S, Janssen PML, et al. Memantine and its benefits for cancer, cardiovascular and neurological disorders. Eur J Pharmacol. 2021;910:174455. doi:10.1016/j.ejphar.2021.174455
   PubMed Web of Science ®Google Scholar
• Estrada LD, Oliveira-Cruz L, Cabrera D. Transforming Growth Factor Beta Type I Role in Neurodegeneration: Implications for Alzheimer´s Disease. Curr Protein Pept Sci. 2018;19(12):1180–1188. doi:10.2174/1389203719666171129094937
   PubMed Web of Science ®Google Scholar
• Lee M, Lin S-R, Chang J-Y, et al. TGF-β induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid β plaques in Alzheimer’s disease. Cell Death Dis. 2010;1(12):e110–e110. doi:10.1038/cddis.2010.83
   PubMedGoogle Scholar
• Chang H-T, Liu -C-C, Chen S-T, et al. WW domain-containing oxidoreductase in neuronal injury and neurological diseases. Oncotarget. 2014;5(23):11792. doi:10.18632/oncotarget.2961
   PubMedGoogle Scholar
• Chou P-Y, Lin S-R, Lee M-H, et al. A p53/TIAF1/WWOX triad exerts cancer suppression but may cause brain protein aggregation due to p53/WWOX functional antagonism. Cell Commun Signal. 2019;17(1):1–16. doi:10.1186/s12964-019-0382-y
   PubMedGoogle Scholar
• Lee M-H, Shih YH, Yap YV, et al. Zfra restores memory deficits in Alzheimer’s disease triple-transgenic mice by blocking aggregation of TRAPPC6AΔ, SH3GLB2, tau, and amyloid β, and inflammatory NF-κB activation. Alzheimer's Dement. 2017;3(2):189–204.
   Google Scholar
• Chang NS. Zfra regulates protein degradation and provides strong prevention against skin cancer. Cancer Research. 2011;71(8_Supplement):4621.
   Google Scholar
• Guo T, Zhang D, Zeng Y, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol Neurodegener. 2020;15(1):1–37. doi:10.1186/s13024-019-0350-4
   PubMed Web of Science ®Google Scholar
• Ruffini N, Klingenberg S, Schweiger S, et al. Common factors in neurodegeneration: a meta-study revealing shared patterns on a multi-omics scale. Cells. 2020;9(12):2642. doi:10.3390/cells9122642
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ni K, Deng H, et al. Dancing with reactive oxygen species generation and elimination in nanotheranostics for disease treatment. Adv Drug Deliv Rev. 2020;158:73–90. doi:10.1016/j.addr.2020.06.006
   PubMed Web of Science ®Google Scholar
• Hook V, Yoon M, Mosier C, et al. Cathepsin B in neurodegeneration of Alzheimer’s disease, traumatic brain injury, and related brain disorders. Biochim Biophys Acta Proteins Proteom. 2020;1868(8):140428. doi:10.1016/j.bbapap.2020.140428
   PubMed Web of Science ®Google Scholar
• Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21(10):1359–1369. doi:10.1038/s41593-018-0242-x
   PubMed Web of Science ®Google Scholar
• Ernest James Phillips T, Maguire E. Phosphoinositides: roles in the development of microglial-mediated neuroinflammation and neurodegeneration. Front Cell Neurosci. 2021;15:90.
   Web of Science ®Google Scholar
• Desale SE, Chinnathambi S. Phosphoinositides signaling modulates microglial actin remodeling and phagocytosis in Alzheimer’s disease. Cell Commun Signal. 2021;19(1):1–12. doi:10.1186/s12964-021-00715-0
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Routhe LJ, Moos T. The vascular basement membrane in the healthy and pathological brain. J Cereb Blood Flow Metab. 2017;37(10):3300–3317. doi:10.1177/0271678X17722436
   PubMed Web of Science ®Google Scholar
• Gaspar R, Meisl G, Buell AK, et al. Secondary nucleation of monomers on fibril surface dominates α -synuclein aggregation and provides autocatalytic amyloid amplification. Q Rev Biophys. 2017;50. doi:10.1017/S0033583516000172
   PubMed Web of Science ®Google Scholar
• Michaels TCT, Šarić A, Curk S, et al. Dynamics of oligomer populations formed during the aggregation of Alzheimer’s Aβ42 peptide. Nat Chem. 2020;12(5):445–451. doi:10.1038/s41557-020-0452-1
   PubMed Web of Science ®Google Scholar
• Malishev R, Nandi S, Śmiłowicz D, et al. Interactions between BIM protein and beta-amyloid may reveal a crucial missing link between Alzheimer’s disease and neuronal cell death. ACS Chem Neurosci. 2019;10(8):3555–3564. doi:10.1021/acschemneuro.9b00177
   PubMed Web of Science ®Google Scholar
• Tang Y, Gao J, Wang T, et al. The effect of drug loading and multiple administration on the protein corona formation and brain delivery property of PEG-PLA nanoparticles. Acta Pharm Sin B. 2021;2021:1.
   Google Scholar
• Huang Q, Zhao Q, Peng J, et al. Peptide–polyphenol (KLVFF/EGCG) binary modulators for inhibiting aggregation and neurotoxicity of amyloid-β peptide. ACS Omega. 2019;4(2):4233–4242. doi:10.1021/acsomega.8b02797
   Web of Science ®Google Scholar
• Liu H, Yu L, Dong X, et al. Synergistic effects of negatively charged hydrophobic nanoparticles and (−)-epigallocatechin-3-gallate on inhibiting amyloid β-protein aggregation. J Colloid Interface Sci. 2017;491:305–312. doi:10.1016/j.jcis.2016.12.038
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhou X, Yu Q, et al. Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity. ACS Appl Mater Interfaces. 2014;6(11):8475–8487. doi:10.1021/am501341u
   PubMed Web of Science ®Google Scholar
• Mourtas S, Lazar AN, Markoutsa E, et al. Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur J Med Chem. 2014;80:175–183. doi:10.1016/j.ejmech.2014.04.050
   PubMed Web of Science ®Google Scholar
• Papakyriakopoulou P, Manta K, Kostantini C, et al. Nasal powders of quercetin-β-cyclodextrin derivatives complexes with mannitol/lecithin microparticles for Nose-to-Brain delivery: In vitro and ex vivo evaluation. Int J Pharm. 2021;607:121016. doi:10.1016/j.ijpharm.2021.121016
   PubMedGoogle Scholar
• Tong-un T, Muchimapura S, Wattanathorn J, Phachonpai W. Nasal Administration of Quercetin Liposomes Improves Memory Impairment and Neurodegeneration in Animal Model of Alzheimer’s Disease. Am J Agric Biol Sci. 2010;5(3):286–293. doi:10.3844/ajabssp.2010.286.293
   Google Scholar
• Kuo Y-C, Chen I-Y, Rajesh R. Use of functionalized liposomes loaded with antioxidants to permeate the blood–brain barrier and inhibit β-amyloid-induced neurodegeneration in the brain. J Taiwan Inst Chem Eng. 2018;87:1–14. doi:10.1016/j.jtice.2018.03.001
   Web of Science ®Google Scholar
• Sawda C, Moussa C, Turner RS. Resveratrol for Alzheimer’s disease. Ann N Y Acad Sci. 2017;1403(1):142–149. doi:10.1111/nyas.13431
   PubMed Web of Science ®Google Scholar
• Santos AC, Pereira I, Pereira-Silva M, et al. Nanotechnology-based formulations for resveratrol delivery: Effects on resveratrol in vivo bioavailability and bioactivity. Colloids Surf B Biointerfaces. 2019;180:127–140. doi:10.1016/j.colsurfb.2019.04.030
   PubMed Web of Science ®Google Scholar
• Sharma HS, Muresanu DF, Castellani RJ, et al. Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer’s disease. Prog Brain Res. 2019;245:145–200. doi:10.1016/bs.pbr.2019.03.009
   PubMed Web of Science ®Google Scholar
• Li Q, Wu Y, Chen J, et al. Microglia and immunotherapy in Alzheimer’s disease. Acta Neurol Scand. 2022;145(3):273–278. doi:10.1111/ane.13551
   PubMed Web of Science ®Google Scholar
• Eloy JO, Petrilli R, Trevizan LNF, et al. Immunoliposomes: a review on functionalization strategies and targets for drug delivery. Colloids Surf B Biointerfaces. 2017;159:454–467. doi:10.1016/j.colsurfb.2017.07.085
   PubMed Web of Science ®Google Scholar
• Bachurin SO, Bovina EV, Ustyugov AA. Drugs in clinical trials for Alzheimer’s disease: the major trends. Med Res Rev. 2017;37(5):1186–1225. doi:10.1002/med.21434
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu L-P, Dai W, et al. Graphene quantum dots for the inhibition of β amyloid aggregation. Nanoscale. 2015;7(45):19060–19065. doi:10.1039/C5NR06282A
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu F, Sun X, et al. Engineering carbon nanotube fiber for real-time quantification of ascorbic acid levels in a live rat model of Alzheimer’s disease. Anal Chem. 2017;89(3):1831–1837. doi:10.1021/acs.analchem.6b04168
   PubMed Web of Science ®Google Scholar
• Gregory WE, Sharma B, Hu L, et al. Interfacial charge transfer with exfoliated graphene inhibits fibril formation in lysozyme amyloid. Biointerphases. 2020;15(3):031010. doi:10.1116/6.0000019
   PubMed Web of Science ®Google Scholar
• Zhang W, Sigdel G, Mintz KJ, et al. Carbon dots: A future Blood–Brain Barrier penetrating nanomedicine and drug nanocarrier. Int J Nanomedicine. 2021;16:5003. doi:10.2147/IJN.S318732
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liyanage PY, Devadoss D, et al. Nontoxic amphiphilic carbon dots as promising drug nanocarriers across the blood–brain barrier and inhibitors of β-amyloid. Nanoscale. 2019;11(46):22387–22397. doi:10.1039/C9NR08194A
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu L-P, Wang Q, et al. Synergistic inhibitory effect of GQDs–tramiprosate covalent binding on amyloid aggregation. ACS Chem Neurosci. 2018;9(4):817–823. doi:10.1021/acschemneuro.7b00439
   PubMed Web of Science ®Google Scholar
• Gong X, Zhang Q, Gao Y, et al. Phosphorus and nitrogen dual-doped hollow carbon dot as a nanocarrier for doxorubicin delivery and biological imaging. ACS Appl Mater Interfaces. 2016;8(18):11288–11297. doi:10.1021/acsami.6b01577
   PubMed Web of Science ®Google Scholar
• Chung YJ, Kim K, Lee BI, et al. Carbon Nanodot‐Sensitized Modulation of Alzheimer’s β‐Amyloid Self‐Assembly, Disassembly, and Toxicity. Small. 2017;13(34):1700983. doi:10.1002/smll.201700983
   Google Scholar
• Stelmashook E, Isaev NK, Genrikhs EE, et al. Role of zinc and copper ions in the pathogenetic mechanisms of Alzheimer’s and Parkinson’s diseases. Biochemistry. 2014;79(5):391–396. doi:10.1134/S0006297914050022
   PubMed Web of Science ®Google Scholar
• James SA, Churches QI, de Jonge MD, et al. Iron, copper, and zinc concentration in Aβ plaques in the APP/PS1 mouse model of Alzheimer’s disease correlates with metal levels in the surrounding neuropil. ACS Chem Neurosci. 2017;8(3):629–637. doi:10.1021/acschemneuro.6b00362
   PubMed Web of Science ®Google Scholar
• Pithadia AS, Lim MH. Metal-associated amyloid-β species in Alzheimer’s disease. Curr Opin Chem Biol. 2012;16(1–2):67–73. doi:10.1016/j.cbpa.2012.01.016
   PubMed Web of Science ®Google Scholar
• Vilella A, Belletti D, Sauer AK, et al. Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer’s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery. J Trace Elem Med Biol. 2018;49:210–221. doi:10.1016/j.jtemb.2017.12.006
   PubMed Web of Science ®Google Scholar
• Sun D, Zhang W, Yu Q, et al. Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid β aggregation for treating Alzheimer’s disease. J Colloid Interface Sci. 2017;505:1001–1010. doi:10.1016/j.jcis.2017.06.083
   PubMed Web of Science ®Google Scholar
• Mittapelly N, Thalla M, Pandey G, et al. Long acting ionically paired embonate based nanocrystals of donepezil for the treatment of Alzheimer’s disease: a proof of concept study. Pharm Res. 2017;34(11):2322–2335. doi:10.1007/s11095-017-2240-1
   PubMed Web of Science ®Google Scholar
• Krishna KV, Wadhwa G, Alexander A, et al. Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery. ACS Chem Neurosci. 2019;10(9):4124–4135. doi:10.1021/acschemneuro.9b00343
   PubMed Web of Science ®Google Scholar
• Pagar KP, Sardar SM, Vavia PR. Novel L-Lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer’s disease. J Biomed Nanotechnol. 2014;10(3):415–426. doi:10.1166/jbn.2014.1719
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Dung Nguyen TT, Vo TK, et al. Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother. 2021;143:112117. doi:10.1016/j.biopha.2021.112117
   PubMed Web of Science ®Google Scholar
• MacLeod R, Hillert E-K, Cameron RT, et al. The role and therapeutic targeting of α-, β-and γ-secretase in Alzheimer’s disease. Future Sci OA. 2015;1(3). doi:10.4155/fso.15.9
   PubMedGoogle Scholar
• Imamura Y, Umezawa N, Osawa S, et al. Effect of helical conformation and side chain structure on γ-secretase inhibition by β-peptide foldamers: insight into substrate recognition. J Med Chem. 2013;56(4):1443–1454. doi:10.1021/jm301306c
   PubMed Web of Science ®Google Scholar
• Rassu G, Soddu E, Posadino AM, et al. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloids Surf B Biointerfaces. 2017;152:296–301. doi:10.1016/j.colsurfb.2017.01.031
   PubMed Web of Science ®Google Scholar
• Zheng M, Tao W, Zou Y, et al. Nanotechnology-based strategies for siRNA brain delivery for disease therapy. Trends Biotechnol. 2018;36(5):562–575. doi:10.1016/j.tibtech.2018.01.006
   PubMed Web of Science ®Google Scholar
• Wang P, Zheng X, Guo Q, et al. Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer’s disease. J Control Release. 2018;279:220–233. doi:10.1016/j.jconrel.2018.04.034
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhu F, Liu Y, et al. Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy. Sci Adv. 2020;6(41):eabc7031. doi:10.1126/sciadv.abc7031
   PubMed Web of Science ®Google Scholar
• Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88(1):487–514. doi:10.1146/annurev-biochem-013118-111902
   PubMed Web of Science ®Google Scholar
• Snyder A, Grunseich C. Hitching a ride on exosomes: a new approach for the delivery of siRNA-mediated therapies. Brain. 2021;144(11):3286–3287. doi:10.1093/brain/awab398
   PubMedGoogle Scholar
• Urban AS, Pavlov KV, Kamynina AV, et al. Structural Studies Providing Insights into Production and Conformational Behavior of Amyloid-β Peptide Associated with Alzheimer’s Disease Development. Molecules. 2021;26(10):2897. doi:10.3390/molecules26102897
   PubMed Web of Science ®Google Scholar
• Song C, Shi J, Zhang P, et al. Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond. Transl Neurodegener. 2022;11(1):1–17. doi:10.1186/s40035-022-00292-3
   PubMed Web of Science ®Google Scholar
• Farizatto KLG, Ikonne US, Almeida MF, et al. Aβ42-mediated proteasome inhibition and associated tau pathology in hippocampus are governed by a lysosomal response involving cathepsin B: Evidence for protective crosstalk between protein clearance pathways. PLoS One. 2017;12(8):e0182895. doi:10.1371/journal.pone.0182895
   PubMed Web of Science ®Google Scholar
• Xiao S, Song -L-L, Li J-T, et al. Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ 42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice. J Alzheimer's Dis. 2020;73(2):657–670. doi:10.3233/JAD-190874
   PubMed Web of Science ®Google Scholar
• Usman M, Bhardwaj S, Roychoudhury S, et al. Immunotherapy for Alzheimer’s disease: current scenario and future perspectives. J Prev Alzheimer's Dis. 2021;8(4):534–551. doi:10.14283/jpad.2021.52
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Painter MM, Bu G, et al. Apolipoprotein E as a therapeutic target in Alzheimer’s disease: a review of basic research and clinical evidence. CNS drugs. 2016;30(9):773–789. doi:10.1007/s40263-016-0361-4
   PubMed Web of Science ®Google Scholar
• Huang Y-WA, Zhou B, Nabet AM, et al. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer’s Disease Risk. The Journal of Neuroscience. 2019;39(37):7408–7427. doi:10.1523/JNEUROSCI.2994-18.2019
   PubMed Web of Science ®Google Scholar
• Davis AA, Inman CE, Wargel ZM, et al. APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med. 2020;12(529):eaay3069. doi:10.1126/scitranslmed.aay3069
   PubMed Web of Science ®Google Scholar
• Zhao N, Urban AS, Pavlov KV, et al. APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med. 2020;12(529):eaay1809. doi:10.1126/scitranslmed.aay1809
   PubMed Web of Science ®Google Scholar
• Chai AB, Lam HH, Kockx M, Gelissen IC. Apolipoprotein E isoform-dependent effects on the processing of Alzheimer’s amyloid-β. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(9):158980.
   PubMed Web of Science ®Google Scholar
• Frieden C, Wang H, Ho CM. A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain–domain interactions. Proc Natl Acad Sci. 2017;114(24):6292–6297. doi:10.1073/pnas.1705080114
   PubMed Web of Science ®Google Scholar
• Chen Y, Strickland MR, Soranno A, et al. Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis. Neuron. 2021;109(2):205–221. doi:10.1016/j.neuron.2020.10.008
   PubMed Web of Science ®Google Scholar
• Wang C, Najm R, Xu Q, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med. 2018;24(5):647–657. doi:10.1038/s41591-018-0004-z
   PubMed Web of Science ®Google Scholar
• Montazersaheb S, Ahmadian E, Dizaj SM, et al. Emerging Nanotherapeutic Alzheimer’s Disease. Front Clin Drug Res. 2021;2:173.
   Google Scholar
• Martin-Rapun R, De Matteis L, Ambrosone A, et al. Targeted Nanoparticles for the Treatment of Alzheimer’s Disease. Curr Pharm Des. 2017;23(13):1927–1952. doi:10.2174/1381612822666161226151011
   PubMed Web of Science ®Google Scholar
• Kong N, Deng M, Sun X-N, et al. Polydopamine-functionalized CA-(PCL-ran-PLA) nanoparticles for target delivery of docetaxel and chemo-photothermal therapy of breast cancer. Front Pharmacol. 2018;9:125. doi:10.3389/fphar.2018.00125
   PubMed Web of Science ®Google Scholar
• Su S, Kang PM. Systemic review of biodegradable nanomaterials in nanomedicine. Nanomaterials. 2020;10(4):656. doi:10.3390/nano10040656
   Web of Science ®Google Scholar
• Griffin S, Masood M, Nasim M, et al. Natural nanoparticles: a particular matter inspired by nature. Antioxidants. 2017;7(1):3. doi:10.3390/antiox7010003
   Web of Science ®Google Scholar
• Ibarra LE, Beaugé L, Arias-Ramos N, et al. Trojan horse monocyte-mediated delivery of conjugated polymer nanoparticles for improved photodynamic therapy of glioblastoma. Nanomedicine. 2020;15(17):1687–1707. doi:10.2217/nnm-2020-0106
   PubMed Web of Science ®Google Scholar
• Casamonti M, Risaliti L, Vanti G, et al. Andrographolide loaded in micro-and nano-formulations: improved bioavailability, target-tissue distribution, and efficacy of the “king of bitters”. Engineering. 2019;5(1):69–75. doi:10.1016/j.eng.2018.12.004
   Web of Science ®Google Scholar
• Zhang C, Song J, Lou L, et al. Doxorubicin‐loaded nanoparticle coated with endothelial cells‐derived exosomes for immunogenic chemotherapy of glioblastoma. Bioeng Transl Med. 2021;6(3):e10203. doi:10.1002/btm2.10203
   PubMed Web of Science ®Google Scholar
• Kaushal N. Double-Coated Biodegradable Poly (Butyl Cyanoacrylate) Nanoparticulate Delivery Systems for Brain Targeting of Doxorubicin via Oral Administration. New York: St. John’s University; 2021.
   Google Scholar
• Wiwatchaitawee K, Quarterman JC, Geary SM, et al. Enhancement of therapies for glioblastoma (GBM) using nanoparticle-based delivery systems. AAPS PharmSciTech. 2021;22(2):1–16. doi:10.1208/s12249-021-01928-9
   Web of Science ®Google Scholar
• Pereverzeva E, Treschalin I, Bodyagin D, et al. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio-and testicular toxicity. Int J Pharm. 2007;337(1–2):346–356. doi:10.1016/j.ijpharm.2007.01.031
   PubMed Web of Science ®Google Scholar
• Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine. 2018;13:3921. doi:10.2147/IJN.S165210
   PubMed Web of Science ®Google Scholar
• Marques A, Costa PJ, Velho S, et al. Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies. J Control Release. 2020;320:180–200. doi:10.1016/j.jconrel.2020.01.035
   PubMed Web of Science ®Google Scholar
• Kaźmierczak Z, Szostak-Paluch K, Przybyło M, et al. Endocytosis in cellular uptake of drug delivery vectors: Molecular aspects in drug development. Bioorg Med Chem. 2020;28(18):115556. doi:10.1016/j.bmc.2020.115556
   PubMed Web of Science ®Google Scholar
• Vora P, Venugopal C, Salim SK, et al. The rational development of CD133-targeting immunotherapies for glioblastoma. Cell Stem Cell. 2020;26(6):832–844. e6. doi:10.1016/j.stem.2020.04.008
   PubMed Web of Science ®Google Scholar
• Zhu X, Prasad S, Gaedicke S, et al. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget. 2015;6(1):171. doi:10.18632/oncotarget.2767
   PubMed Web of Science ®Google Scholar
• Jhaveri A, Deshpande P, Pattni B, et al. Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release. 2018;277:89–101. doi:10.1016/j.jconrel.2018.03.006
   PubMed Web of Science ®Google Scholar
• Devarajan PV, Dandekar P, D’Souza AA. Targeted Intracellular Drug Delivery by Receptor Mediated Endocytosis. Springer; 2019.
   Google Scholar
• Zheng M, Ruan S, Liu S, et al. Self-targeting fluorescent carbon dots for diagnosis of brain cancer cells. ACS nano. 2015;9(11):11455–11461. doi:10.1021/acsnano.5b05575
   PubMed Web of Science ®Google Scholar
• Qiao L, Sun T, Zheng X, et al. Exploring the optimal ratio of d-glucose/l-aspartic acid for targeting carbon dots toward brain tumor cells. Mater Sci Eng C. 2018;85:1–6. doi:10.1016/j.msec.2017.12.011
   PubMed Web of Science ®Google Scholar
• Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 2002;54(4):561–587. doi:10.1124/pr.54.4.561
   PubMed Web of Science ®Google Scholar
• Hettiarachchi SD, Graham RM, Mintz KJ, et al. Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors. Nanoscale. 2019;11(13):6192–6205. doi:10.1039/C8NR08970A
   PubMed Web of Science ®Google Scholar
• Liyanage PY, Zhou Y, Al-Youbi AO, et al. Pediatric glioblastoma target-specific efficient delivery of gemcitabine across the blood–brain barrier via carbon nitride dots. Nanoscale. 2020;12(14):7927–7938. doi:10.1039/D0NR01647K
   PubMed Web of Science ®Google Scholar
• Sun T, Patil R, Galstyan A, et al. Blockade of a laminin-411–notch axis with CRISPR/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment cross-talk. Cancer Res. 2019;79(6):1239–1251. doi:10.1158/0008-5472.CAN-18-2725
   PubMed Web of Science ®Google Scholar
• Ljubimova JY. In vivo targeting of laminin-411-β1 integrin-Notch signaling pathway using nanobioconjugate alters glioma microenvironment for effective treatment. AACR; 2017.
   Google Scholar
• Canfarotta F, Lezina L, Guerreiro A, et al. Specific drug delivery to cancer cells with double-imprinted nanoparticles against epidermal growth factor receptor. Nano Lett. 2018;18(8):4641–4646. doi:10.1021/acs.nanolett.7b03206
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu Q, Du M, et al. Cetuximab and Doxorubicin loaded dextran-coated Fe3O4 magnetic nanoparticles as novel targeted nanocarriers for non-small cell lung cancer. J Magn Magn Mater. 2019;481:122–128. doi:10.1016/j.jmmm.2019.01.021
   Web of Science ®Google Scholar
• Katsushima K, Natsume A, Ohka F, et al. Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun. 2016;7(1):1–14. doi:10.1038/ncomms13616
   Google Scholar
• Hsu SPC, Dhawan U, Tseng -Y-Y, et al. Glioma-sensitive delivery of Angiopep-2 conjugated iron gold alloy nanoparticles ensuring simultaneous tumor imaging and hyperthermia mediated cancer theranostics. Appl Mater Today. 2020;18:100510. doi:10.1016/j.apmt.2019.100510
   Web of Science ®Google Scholar
• Wang M, Kuang R, Huang B, et al. Polylactic acid block copolymer grafted temozolomide targeted nano delivery in the treatment of glioma. Mater Express. 2021;11(5):627–633. doi:10.1166/mex.2021.1961
   Web of Science ®Google Scholar
• Xuan S, Shin DH, Kim J-S. Angiopep-2-conjugated liposomes encapsulating γ-secretase inhibitor for targeting glioblastoma stem cells. J Pharm Investig. 2014;44(7):473–483. doi:10.1007/s40005-014-0151-2
   Google Scholar
• Xu H, Li C, Wei Y, et al. Angiopep-2-modified calcium arsenite-loaded liposomes for targeted and pH-responsive delivery for anti-glioma therapy. Biochem Biophys Res Commun. 2021;551:14–20. doi:10.1016/j.bbrc.2021.02.138
   PubMed Web of Science ®Google Scholar
• Liu Y, Mei L, Yu Q, et al. Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma. ACS Appl Mater Interfaces. 2015;7(30):16792–16801. doi:10.1021/acsami.5b04596
   PubMed Web of Science ®Google Scholar
• Wang Y, Ying X, Xu H, et al. The functional curcumin liposomes induce apoptosis in C6 glioblastoma cells and C6 glioblastoma stem cells in vitro and in animals. Int J Nanomedicine. 2017;12:1369. doi:10.2147/IJN.S124276
   PubMed Web of Science ®Google Scholar
• Shi M, Anantha M, Wehbe M, et al. Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats. J Nanobiotechnology. 2018;16(1):1–12. doi:10.1186/s12951-018-0404-8
   PubMedGoogle Scholar
• Xia P, Li Q, Wu G, et al. An immune-related lncRNA signature to predict survival in glioma patients. Cell Mol Neurobiol. 2021;41(2):365–375. doi:10.1007/s10571-020-00857-8
   PubMed Web of Science ®Google Scholar
• Sriraman A. Targeting MDM2, the antagonist of the tumor suppressor p53. Niedersächsische Staats-und Universitätsbibliothek Göttingen; 2018.
   Google Scholar
• Yang R, Cai TT, Wu XJ, et al. Tumour YAP1 and PTEN expression correlates with tumour‐associated myeloid suppressor cell expansion and reduced survival in colorectal cancer. Immunology. 2018;155(2):263–72.
   PubMed Web of Science ®Google Scholar
• Kreatsoulas D, Bolyard C, Wu BX, et al. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. J Hematol Oncol. 2022;15(1):1–30.
   PubMed Web of Science ®Google Scholar
• Loya J, Zhang C, Cox E, et al. Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins. CNS Oncol. 2019;8(3):CNS38. doi:10.2217/cns-2019-0001
   PubMedGoogle Scholar
• Mohammed S, Shamseddine AA, Newcomb B, et al. Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases. Breast Cancer Res. 2021;23(1):1–20. doi:10.1186/s13058-021-01452-5
   PubMed Web of Science ®Google Scholar
• Wang T, Tang J, Yang H, et al. Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: the APPROVE randomized clinical trial. JAMA Oncol. 2022;8(8):1169–1176. doi:10.1001/jamaoncol.2022.2253
   PubMed Web of Science ®Google Scholar
• Riley RS, June CH, Langer R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–196. doi:10.1038/s41573-018-0006-z
   PubMed Web of Science ®Google Scholar
• Feng X, Xu W, Liu J, et al. Polypeptide nanoformulation-induced immunogenic cell death and remission of immunosuppression for enhanced chemoimmunotherapy. Sci Bull. 2021;66(4):362–373. doi:10.1016/j.scib.2020.07.013
   PubMed Web of Science ®Google Scholar
• Ding Y, Xu Y, Yang W, et al. Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy. Nano Today. 2020;35:100970. doi:10.1016/j.nantod.2020.100970
   Web of Science ®Google Scholar
• Singh PK, Srivastava AK, Dev A, et al. 1, 3β-Glucan anchored, paclitaxel loaded chitosan nanocarrier endows enhanced hemocompatibility with efficient anti-glioblastoma stem cells therapy. Carbohydr Polym. 2018;180:365–375. doi:10.1016/j.carbpol.2017.10.030
   PubMed Web of Science ®Google Scholar
• Dorababu A. Recent Advances in Nanoformulated Chemotherapeutic Drug Delivery (2015‐2019). ChemistrySelect. 2019;4(29):8731–8744. doi:10.1002/slct.201901064
   Web of Science ®Google Scholar
• Joshi HA, Patwardhan RS, Sharma D, et al. Pre-clinical evaluation of an innovative oral nano-formulation of baicalein for modulation of radiation responses. Int J Pharm. 2021;595:120181. doi:10.1016/j.ijpharm.2020.120181
   PubMedGoogle Scholar
• Frankel BM, Cachia D, Patel SJ, et al. Targeting subventricular zone progenitor cells with intraventricular liposomal encapsulated cytarabine in patients with secondary glioblastoma: A report of two cases. SN Compr Clin Med. 2020;2(6):836–843. doi:10.1007/s42399-020-00322-z
   PubMedGoogle Scholar
• Ahmadzada T, Reid G, McKenzie DR. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophys Rev. 2018;10(1):69–86. doi:10.1007/s12551-017-0392-1
   PubMedGoogle Scholar
• Rahman M, Alharbi KS, Alruwaili NK, et al. Nucleic acid-loaded lipid-polymer nanohybrids as novel nanotherapeutics in anticancer therapy. Expert Opin Drug Deliv. 2020;17(6):805–816. doi:10.1080/17425247.2020.1757645
   PubMed Web of Science ®Google Scholar
• Ferreira D, Fontinha D, Martins C, et al. Gold nanoparticles for vectorization of nucleic acids for cancer therapeutics. Molecules. 2020;25(15):3489. doi:10.3390/molecules25153489
   PubMed Web of Science ®Google Scholar
• Galli M, Guerrini A, Cauteruccio S, et al. Superparamagnetic iron oxide nanoparticles functionalized by peptide nucleic acids. RSC Adv. 2017;7(25):15500–15512. doi:10.1039/C7RA00519A
   Web of Science ®Google Scholar
• Li C, Dou Y, Chen Y, et al. Site‐specific microRNA‐33 antagonism by pH‐responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity. Adv Funct Mater. 2020;30(42):2002131. doi:10.1002/adfm.202002131
   Web of Science ®Google Scholar
• Liu Y, Zhang D, An Y, et al. Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma. Nano Today. 2023;49:101790. doi:10.1016/j.nantod.2023.101790
   Web of Science ®Google Scholar
• Wang Y, Sun Y, Geng N, et al. A Biomimetic Nanomedicine Targets Orthotopic Glioblastoma by Combinatorial Co‐Delivery of Temozolomide and a Methylguanine‐DNA Methyltransferase Inhibitor. Adv Ther. 2022;5(12):2200095. doi:10.1002/adtp.202200095
   Google Scholar
• Kubiatowicz LJ, Mohapatra A, Krishnan N, Fang RH, Zhang L. mRNA nanomedicine: Design and recent applications. In: Exploration. Wiley Online Library; 2022.
   Google Scholar
• Shah U, Joshi G, Sawant K. Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design. Mater Sci Eng C. 2014;35:153–163. doi:10.1016/j.msec.2013.10.038
   PubMed Web of Science ®Google Scholar
• Binda A, Murano C, Rivolta I. Innovative therapies and nanomedicine applications for the treatment of Alzheimer’s disease: a state-of-the-art (2017–2020). Int J Nanomedicine. 2020;15:6113. doi:10.2147/IJN.S231480
   PubMed Web of Science ®Google Scholar
• Tóth OM, Menyhárt Á, Varga VÉ, et al. Chitosan nanoparticles release nimodipine in response to tissue acidosis to attenuate spreading depolarization evoked during forebrain ischemia. Neuropharmacology. 2020;162:107850. doi:10.1016/j.neuropharm.2019.107850
   PubMed Web of Science ®Google Scholar
• Remya P, Damodharan N. Formulation, development and characterisation of nimodipine loaded solid lipid nanoparticles. Int J App Pharm. 2020;2020:265–271.
   Google Scholar
• Sha’at F, Pavaloiu RD, Salceanu DC, et al. Formulation of Polymeric Multicomponent Systems Containing Cardiovascular APIs. Mater Plast. 2018;55(1):121. doi:10.37358/MP.18.1.4976
   Web of Science ®Google Scholar
• Alawdi SH, Eidi H, Safar MM, et al. Loading amlodipine on diamond nanoparticles: A novel drug delivery system. Nanotechnol Sci Appl. 2020;12:47. doi:10.2147/NSA.S232517
   Web of Science ®Google Scholar
• Fathi-Achachelouei M, Knopf-Marques H, Ribeiro da Silva CE, et al. Use of nanoparticles in tissue engineering and regenerative medicine. Front Bioeng Biotechnol. 2019;7:113. doi:10.3389/fbioe.2019.00113
   PubMed Web of Science ®Google Scholar
• Yuan M, Wang Y, Qin Y-X. Engineered nanomedicine for neuroregeneration: light emitting diode-mediated superparamagnetic iron oxide-gold core-shell nanoparticles functionalized by nerve growth factor. Nanomedicine. 2019;21:102052. doi:10.1016/j.nano.2019.102052
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zhang E, Fu A. Promotion of SH-SY5Y cell growth by gold nanoparticles modified with 6-mercaptopurine and a neuron-penetrating peptide. Nanoscale Res Lett. 2017;12(1):1–9. doi:10.1186/s11671-017-2417-x
   PubMedGoogle Scholar
• Katebi S, Esmaeili A, Ghaedi K, et al. Superparamagnetic iron oxide nanoparticles combined with NGF and quercetin promote neuronal branching morphogenesis of PC12 cells. Int J Nanomedicine. 2019;14:2157. doi:10.2147/IJN.S191878
   PubMed Web of Science ®Google Scholar
• Wójtowicz S, Strosznajder AK, Jeżyna M, et al. The novel role of PPAR alpha in the brain: promising target in therapy of Alzheimer’s disease and other neurodegenerative disorders. Neurochem Res. 2020;45(5):972–988. doi:10.1007/s11064-020-02993-5
   PubMed Web of Science ®Google Scholar
• Strosznajder AK, Wójtowicz S, Jeżyna MJ, et al. Recent insights on the role of PPAR-β/δ in neuroinflammation and neurodegeneration, and its potential target for therapy. Neuromolecular Med. 2020:1–13. doi:10.1007/s12017-019-08556-4
   PubMed Web of Science ®Google Scholar
• Wagner N, Wagner K-D. PPAR beta/delta and the hallmarks of cancer. Cells. 2020;9(5):1133. doi:10.3390/cells9051133
   PubMed Web of Science ®Google Scholar
• Silva-Abreu M, Calpena AC, Andrés-Benito P, et al. PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer’s disease: in vitro and in vivo studies. Int J Nanomedicine. 2018;13:5577. doi:10.2147/IJN.S171490
   PubMed Web of Science ®Google Scholar
• Carradori D, Balducci C, Re F, et al. Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer’s disease-like transgenic mouse model. Nanomedicine. 2018;14(2):609–618. doi:10.1016/j.nano.2017.12.006
   PubMed Web of Science ®Google Scholar
• Sun J, Xie W, Zhu X, et al. Sulfur nanoparticles with novel morphologies coupled with brain-targeting peptides RVG as a new type of inhibitor against metal-induced aβ aggregation. ACS Chem Neurosci. 2017;9(4):749–761. doi:10.1021/acschemneuro.7b00312
   PubMed Web of Science ®Google Scholar
• Ji D, Wu X, Li D, et al. Protective effects of chondroitin sulphate nano-selenium on a mouse model of Alzheimer’s disease. Int J Biol Macromol. 2020;154:233–245. doi:10.1016/j.ijbiomac.2020.03.079
   PubMed Web of Science ®Google Scholar
• Sun T, Li Y, Huang Y, et al. Targeting glioma stem cells enhances anti-tumor effect of boron neutron capture therapy. Oncotarget. 2016;7(28):43095. doi:10.18632/oncotarget.9355
   PubMedGoogle Scholar
• Qin L, Wang C-Z, Fan H-J, et al. A dual‑targeting liposome conjugated with transferrin and arginine‑glycine‑aspartic acid peptide for glioma‑targeting therapy. Oncol Lett. 2014;8(5):2000–2006. doi:10.3892/ol.2014.2449
   PubMed Web of Science ®Google Scholar
• Caruso G, Caffo M, Raudino G, et al. Antisense oligonucleotides as an innovative therapeutic strategy in the treatment of high-grade gliomas. Recent Pat CNS Drug Discov. 2010;5(1):53–69. doi:10.2174/157488910789753503
   PubMedGoogle Scholar
• Chou S-T, Patil R, Galstyan A, et al. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release. 2016;244:14–23. doi:10.1016/j.jconrel.2016.11.001
   PubMed Web of Science ®Google Scholar
• Kaluzova M, Bouras A, Machaidze R, et al. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget. 2015;6(11):8788. doi:10.18632/oncotarget.3554
   PubMedGoogle Scholar
• Wang X, Zhao Y, Dong S, et al. Cell-penetrating peptide and transferrin co-modified liposomes for targeted therapy of glioma. Molecules. 2019;24(19):3540. doi:10.3390/molecules24193540
   PubMed Web of Science ®Google Scholar
• Kakinen A, Javed I, Davis TP, et al. In vitro and in vivo models for anti-amyloidosis nanomedicines. Nanoscale Horiz. 2021;6(2):95–119. doi:10.1039/D0NH00548G
   PubMed Web of Science ®Google Scholar
• Uddin M, Kabir MT, Niaz K, et al. Molecular insight into the therapeutic promise of flavonoids against Alzheimer’s disease. Molecules. 2020;25(6):1267. doi:10.3390/molecules25061267
   PubMed Web of Science ®Google Scholar
• Rajput AP, Butani SB. Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: Formulation, optimization and in vivo characterization. J Drug Deliv Sci Technol. 2019;51:214–223. doi:10.1016/j.jddst.2019.01.040
   Web of Science ®Google Scholar
• Savla SR, Laddha AP, Kulkarni YA. Pharmacology of apocynin: a natural acetophenone. Drug Metab Rev. 2021;53(4):1–21.
   PubMed Web of Science ®Google Scholar
• Brenza TM, Ghaisas S, Ramirez JEV, et al. Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy. Nanomedicine. 2017;13(3):809–820. doi:10.1016/j.nano.2016.10.004
   PubMed Web of Science ®Google Scholar
• Vaz GR, Hädrich G, Bidone J, et al. Development of nasal lipid nanocarriers containing curcumin for brain targeting. J Alzheimer's Dis. 2017;59(3):961–974. doi:10.3233/JAD-160355
   PubMed Web of Science ®Google Scholar
• Djiokeng Paka G, Doggui S, Zaghmi A, et al. Neuronal Uptake and Neuroprotective Properties of Curcumin-Loaded Nanoparticles on SK-N-SH Cell Line: Role of Poly(lactide- co -glycolide) Polymeric Matrix Composition. Mol Pharm. 2016;13(2):391–403. doi:10.1021/acs.molpharmaceut.5b00611
   PubMedGoogle Scholar
• Sokolik V, Berchenko O, Shulga S. Comparative analysis of nasal therapy with soluble and liposomal forms of curcumin on rats with Alzheimer’s disease model. J Alzheimer's Dis Parkinsonism. 2017;7(357):2161–0460.1000357.
   Google Scholar
• Ishak RA, Mostafa NM, Kamel AO. Stealth lipid polymer hybrid nanoparticles loaded with rutin for effective brain delivery – comparative study with the gold standard (Tween 80): optimization, characterization and biodistribution. Drug Deliv. 2017;24(1):1874–1890. doi:10.1080/10717544.2017.1410263
   PubMed Web of Science ®Google Scholar
• Lohan S, Raza K, Mehta SK, et al. Anti-Alzheimer’s potential of berberine using surface decorated multi-walled carbon nanotubes: a preclinical evidence. Int J Pharm. 2017;530(1–2):263–278. doi:10.1016/j.ijpharm.2017.07.080
   PubMed Web of Science ®Google Scholar
• Su X, Zhang D, Zhang H, et al. Preparation and characterization of angiopep-2 functionalized ginsenoside-Rg3 loaded nanoparticles and the effect on C6 glioma cells. Pharm Dev Technol. 2020;25(3):385–395. doi:10.1080/10837450.2018.1551901
   PubMed Web of Science ®Google Scholar
• Lv L, Yang F, Li H, et al. Brain-targeted co-delivery of β-amyloid converting enzyme 1 shRNA and epigallocatechin-3-gallate by multifunctional nanocarriers for Alzheimer’s disease treatment. IUBMB life. 2020;72(8):1819–1829. doi:10.1002/iub.2330
   PubMed Web of Science ®Google Scholar
• Fan S, Zheng Y, Liu X, et al. Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease. Drug Deliv. 2018;25(1):1091–1102. doi:10.1080/10717544.2018.1461955
   PubMed Web of Science ®Google Scholar
• Ali T, Kim MJ, Rehman SU, et al. Anthocyanin-loaded PEG-gold nanoparticles enhanced the neuroprotection of anthocyanins in an Aβ1–42 mouse model of Alzheimer’s disease. Mol Neurobiol. 2017;54(8):6490–6506. doi:10.1007/s12035-016-0136-4
   PubMed Web of Science ®Google Scholar